Benchmark upgraded Nephros to Speculative Buy from Hold with a $5 price target after the company reported “solid” results for Q4 and 2023 as a whole. The firm, which forecasts that Nephros will post revenues of $17.1M, up 20% year-over-year in FY24, sees a “positive outlook and quarterly comparisons going forward.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NEPH: